10-Q
Quarterly Report
10x Genomics, Inc.
TXG
NASDAQ
CIK: 1770787
File #: 001-39035
Balance Sheet
39 line items · 2 periods
XBRL
| Item | Sep 30, 2024 | Dec 31, 2023 |
|---|---|---|
Assets | ||
Current assets: | ||
Cash and cash equivalents | 398,159,000 | 359,284,000 |
Marketable securities | 0 | 29,411,000 |
Accounts receivable, net | 83,525,000 | 114,832,000 |
Inventory | 94,050,000 | 73,706,000 |
Prepaid expenses and other current assets | 18,159,000 | 18,789,000 |
Total current assets | 593,893,000 | 596,022,000 |
Property and equipment, net | 258,759,000 | 279,571,000 |
Operating lease right-of-use assets | 59,579,000 | 65,361,000 |
Goodwill | 4,511,000 | 4,511,000 |
Intangible assets, net | 16,149,000 | 16,616,000 |
Other noncurrent assets | 4,903,000 | 3,062,000 |
Total assets | 937,794,000 | 965,143,000 |
Liabilities and stockholders’ equity | ||
Current liabilities: | ||
Accounts payable | 26,210,000 | 15,738,000 |
Accrued compensation and related benefits | 30,080,000 | 30,105,000 |
Accrued expenses and other current liabilities | 37,770,000 | 56,648,000 |
Deferred revenue | 17,760,000 | 13,150,000 |
Products and Services, Excluding Grant Revenue | 17,800,000 | — |
Operating lease liabilities | 9,415,000 | 11,521,000 |
Total current liabilities | 121,235,000 | 127,162,000 |
Operating lease liabilities, noncurrent | 76,461,000 | 83,849,000 |
Deferred revenue, noncurrent | 12,349,000 | 8,814,000 |
Other noncurrent liabilities | 4,945,000 | 4,275,000 |
Total liabilities | 214,990,000 | 224,100,000 |
Stockholders’ equity: | ||
Preferred stock | 0 | 0 |
Common stock | 2,000 | 2,000 |
Additional paid-in capital | 2,140,789,000 | 2,025,890,000 |
Accumulated deficit | (1,418,019,000) | (1,284,420,000) |
Accumulated other comprehensive income (loss) | 32,000 | (429,000) |
Total stockholders’ equity | 722,804,000 | 741,043,000 |
Common Stock | 2,000 | 2,000 |
Additional Paid-in Capital | 2,140,789,000 | 2,025,890,000 |
Accumulated Deficit | (1,418,019,000) | (1,284,420,000) |
Accumulated Other Comprehensive Income (Loss) | 32,000 | (429,000) |
Total liabilities and stockholders’ equity | 937,794,000 | 965,143,000 |